Withaferin-A attenuates multiple low doses of Streptozotocin (MLD-STZ) induced type 1 diabetes

Biomedicine and Pharmacotherapy

Volumn 106, Issue , 2018, Pages 1428-1440

  Tekula, Sravani ^a   Khurana, Amit ^a   Anchi, Pratibha ^a   Godugu, Chandraiah ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Inflammation; Oxidative stress; Type 1 diabetes mellitus; Withaferin A

Indexed keywords

CASPASE 3; GLUCOSE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; MALONALDEHYDE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR; WITHAFERIN A; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; BIOLOGICAL MARKER; INTERLEUKIN-6, MOUSE; NFE2L2 PROTEIN, MOUSE; STREPTOZOCIN; WITHANOLIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DNA FRAGMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; LOW DRUG DOSE; MALE; MOUSE; MULTIPLE DRUG DOSE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TUNEL ASSAY; WITHANIA SOMNIFERA; ANIMAL; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; INFLAMMATION; METABOLISM; PANCREAS; PATHOLOGY; TIME FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOPTOSIS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN; INTERLEUKIN-6; MALE; MICE; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NITROSATIVE STRESS; OXIDATIVE STRESS; PANCREAS; STREPTOZOCIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WITHANOLIDES;

EID: 85050292171     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2018.07.090     Document Type: Article

References (63)

1. Rossini, A.A., Like, A.A., Chick, W.L., Appel, M.C., Cahill, G.F., Studies of streptozotocin-induced insulitis and diabetes. Proc. Natl. Acad. Sci. 74:6 (1977), 2485–2489.
2. Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 27:5 (2004), 1047–1053.
3. Bale, S., Sunkoju, M., Reddy, S.S., Swamy, V., Godugu, C., Oropharyngeal aspiration of bleomycin: An alternative experimental model of pulmonary fibrosis developed in Swiss mice. Indian J. Pharmacol. 48:6 (2016), 643–648.
4. Jain, A.K., Thanki, K., Jain, S., Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity. Mol. Pharm. 10:9 (2013), 3459–3474.
5. Godugu, C., Doddapaneni, R., Singh, M., Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC). Colloids Surf. B Biointerfaces 153 (2017), 208–219.
6. Godugu, C., Patel, A.R., Doddapaneni, R., Somagoni, J., Singh, M., Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS One, 9(3), 2014, e89919.
7. Patel, K., Chowdhury, N., Doddapaneni, R., Boakye, C.H., Godugu, C., Singh, M., Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple‐negative breast cancer. J. Pharm. Sci. 104:12 (2015), 4417–4426.
8. Anchi, P., Khurana, A., Bale, S., Godugu, C., The role of plant‐derived products in pancreatitis: experimental and clinical evidence. Phytother. Res. 31:4 (2017), 591–623.
9. El-Abhar, H.S., Schaalan, M.F., Phytotherapy in diabetes: review on potential mechanistic perspectives. World J. Diabetes 5:2 (2014), 176–197.
10. Yeh, G.Y., Eisenberg, D.M., Kaptchuk, T.J., Phillips, R.S., Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26:4 (2003), 1277–1294.
11. Jung, M., Park, M., Lee, H.C., Kang, Y.-H., Kang, E.S., Kim, S.K., Antidiabetic agents from medicinal plants. Curr. Med. Chem. 13:10 (2006), 1203–1218.
12. Hosseini, A., Shafiee-Nick, R., Ghorbani, A., Pancreatic beta cell protection/regeneration with phytotherapy. Braz. J. Pharm. Sci. 51:1 (2015), 1–16.
13. Lavie, D., Glotter, E., Shvo, Y., Constituents of Withania somnifera Dun. III. The side chain of Withaferin A. J. Org. Chem. 30:6 (1965), 1774–1778.
14. Bhattacharya, S.K., Goel, R.K., Kaur, R., Ghosal, S., Antiâ€-stress activity of sitoindosides VII and VIII, new acylsterylglucosides from Withania somnifera. Phytother. Res. 1:1 (1987), 32–37.
15. Bhattacharya, A., Ghosal, S., Bhattacharya, S.K., Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J. Ethnopharmacol. 74:1 (2001), 1–6.
16. Christina, A.J.M., Joseph, D.G., Packialakshmi, M., Kothai, R., Robert, S.J.H., Chidambaranathan, N., Ramasamy, M., Anticarcinogenic activity of Withania somnifera Dunal against Daltons ascitic lymphoma. J. Ethnopharmacol. 93:2 (2004), 359–361.
17. Davis, L., Kuttan, G., Immunomodulatory activity of Withania somnifera. J. Ethnopharmacol. 71:1 (2000), 193–200.
18. Kanak, M.A., Shahbazov, R., Yoshimatsu, G., Levy, M.F., Lawrence, M.C., Naziruddin, B., A small molecule inhibitor of NFκB blocks ER stress and the NLRP3 inflammasome and prevents progression of pancreatitis. J. Gastroenterol., 2016, 1–14.
19. SoRelle, J., Itoh, T., Peng, H., Kanak, M., Sugimoto, K., Matsumoto, S., Levy, M., Lawrence, M., Naziruddin, B., Withaferin A inhibits pro-inflammatory cytokine-induced damage to islets in culture and following transplantation. Diabetologia 56:4 (2013), 814–824.
20. Lee, J., Liu, J., Feng, X., Hernández, M.A.S., Mucka, P., Ibi, D., Choi, J.W., Ozcan, U., Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice. Nat. Med. 22:9 (2016), 1023–1032.
21. O'Brien, B.A., Harmon, B.V., Cameron, D.P., Allan, D.J., Beta‐cell apoptosis is responsible for the development of IDDM in the multiple low‐dose streptozotocin model. J. Pathol. 178:2 (1996), 176–181.
22. Flodstrom, M., Tyrberg, Eizirik, S., Sandler, Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 48:4 (1999), 706–713.
23. Riboulet-Chavey, A., Diraison, F.D.R., Siew, L.K., Wong, F.S., Rutter, G.A., Inhibition of AMP-activated protein kinase protects pancreatic β-cells from cytokine-mediated apoptosis and CD8+ T-Cells“Induced cytotoxicity. Diabetes 57:2 (2008), 415–423.
24. Pereira, S., Veeraraghavan, P., Ghosh, S., Gandhi, M., Animal experimentation and ethics in India: the CPCSEA makes a difference. Altern. Lab. Anim.: ATLA 32 (2004), 411–415.
25. Reddy, D.R., Khurana, A., Bale, S., Ravirala, R., Reddy, V.S.S., Mohankumar, M., Godugu, C., Natural flavonoids silymarin and quercetin improve the brain distribution of co-administered P-gp substrate drugs. SpringerPlus 5:1 (2016), 1618–1626.
26. Stan, S.D., Hahm, E.R., Warin, R., Singh, S.V., Withaferin A causes FOXO3a-and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res. 68:18 (2008), 7661–7669.
27. Lee, J., Liu, J., Feng, X., Hernández, M.A.S., Mucka, P., Ibi, D., Choi, J.W., Ozcan, U., Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice. Nat. Med. 22:9 (2016), 1023–1032.
28. Jadeja, R.N., Urrunaga, N.H., Dash, S., Khurana, S., Saxena, N.K., Withaferin-A reduces acetaminophen-induced liver injury in mice. Biochem. Pharmacol. 97:1 (2015), 122–132.
29. Kanitkar, M., Gokhale, K., Galande, S., Bhonde, R.R., Novel role of curcumin in the prevention of cytokine‖induced islet death in vitro and diabetogenesis in vivo. Br. J. Pharmacol. 155:5 (2008), 702–713.
30. Ratnam, D.V., Chandraiah, G., Sonaje, K., Viswanad, B., Bhardwaj, V., Ramarao, P., Ravikumar, M., A potential therapeutic strategy for diabetes and its complications in the form of co-encapsulated antioxidant nanoparticles (NanoCAPs) of ellagic acid and coenzyme Q10: preparation and evaluation in streptozotocin induced diabetic rats. J. Biomed. Nanotechnol. 4:1 (2008), 33–43.
31. Ohkawa, H., Ohishi, N., Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95:2 (1979), 351–358.
32. Moron, M.S., Depierre, J.W., Mannervik, B., Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim. Biophys. Acta (BBA)-Gen. Subj. 582:1 (1979), 67–78.
33. Sangomla, S., Saifi, M.A., Khurana, A., Godugu, C., Nanoceria ameliorates doxorubicin induced cardiotoxicity: possible mitigation via reduction of oxidative stress and inflammation. J. Trace Elem. Med. Biol. 47 (2018), 53–62.
34. Jain, S., Rathi, V.V., Jain, A.K., Das, M., Godugu, C., Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Nanomedicine 7:9 (2012), 1311–1337.
35. Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1-2 (1976), 248–254.
36. Karkale, S., Khurana, A., Saifi, M.A., Godugu, C., Talla, V., Oropharyngeal administration of silica in Swiss mice: a robust and reproducible model of occupational pulmonary fibrosis. Pulm. Pharmacol. Ther. 51 (2018), 32–40.
37. Takamura, T., Ando, H., Nagai, Y., Yamashita, H., Nohara, E., Kobayashi, K.-I., Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res. Clin. Pract. 44:2 (1999), 107–114.
38. Kumar, G.S., Kulkarni, A., Khurana, A., Kaur, J., Tikoo, K., Selenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathy. Chem. Biol. Interact. 223 (2014), 125–133.
39. Liadis, N., Murakami, K., Eweida, M., Elford, A.R., Sheu, L., Gaisano, H.Y., Hakem, R., Ohashi, P.S., Woo, M., Caspase-3-dependent β-cell apoptosis in the initiation of autoimmune diabetes mellitus. Mol. Cell. Biol. 25:9 (2005), 3620–3629.
40. Rathmann, W., Giani, G., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:10 (2004), 2568–2569.
41. Baynes, J.W., Role of oxidative stress in development of complications in diabetes. Diabetes 40:4 (1991), 405–412.
42. Goyal, S.N., Reddy, N.M., Patil, K.R., Nakhate, K.T., Ojha, S., Patil, C.R., Agrawal, Y.O., Challenges and issues with streptozotocin-induced diabetes–a clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics. Chem. Biol. Interact. 244 (2016), 49–63.
43. Furman, B.L., Streptozotocin‐induced diabetic models in mice and rats. Curr. Protoc. Pharmacol. 5:47 (2015), 1–5 47.20.
44. Eizirik, D.L., Colli, M.L., Ortis, F., The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 5:4 (2009), 219–226.
45. Kanitkar, M., Gokhale, K., Galande, S., Bhonde, R., Novel role of curcumin in the prevention of cytokine‐induced islet death in vitro and diabetogenesis in vivo. Br. J. Pharmacol. 155:5 (2008), 702–713.
46. Rossini, A.A., Williams, R.M., Appel, M.C., Like, A.A., Complete protection from low-dose streptozotocin-induced diabetes in mice. Nature 276:5684 (1978), 182–184.
47. Kolb, H., Immune intervention in type I diabetes mellitus—current clinical and experimental approaches. Exp. Clin. Endocrinol. Diabetes 102:04 (1994), 269–272.
48. Mishra, L.-C., Singh, B.B., Dagenais, S., Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern. Med. Rev. 5:4 (2000), 334–346.
49. Kaileh, M., Berghe, W.V., Heyerick, A., Horion, J., Piette, J., Libert, C., De Keukeleire, D., Essawi, T., Haegeman, G., Withaferin A strongly elicits IκB kinase β hyperphosphorylation concomitant with potent inhibition of its kinase activity. J. Biol. Chem. 282:7 (2007), 4253–4264.
50. Vedi, M., Sabina, E.P., Assessment of hepatoprotective and nephroprotective potential of withaferin A on bromobenzene-induced injury in Swiss albino mice: possible involvement of mitochondrial dysfunction and inflammation. Cell Biol. Toxicol. 32:5 (2016), 373–390.
51. Heyninck, K., Lahtela-Kakkonen, M., Van der Veken, P., Haegeman, G., Berghe, W.V., Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKβ. Biochem. Pharmacol. 91:4 (2014), 501–509.
52. Srinivasan, K., Kaul, C., Ramarao, P., Partial protective effect of rutin on multiple low dose streptozotocin-induced diabetes in mice. Indian J. Pharmacol. 37:5 (2005), 327–328.
53. Santhekadur, P.K., Is Withaferin A, a magic bullet for metabolic syndrome?. Biomed. Pharmacother. 92 (2017), 1135–1137.
54. Palliyaguru, D.L., Chartoumpekis, D.V., Wakabayashi, N., Skoko, J.J., Yagishita, Y., Singh, S.V., Kensler, T.W., Withaferin A induces Nrf2-dependent protection against liver injury: role of Keap1-independent mechanisms. Free Radic. Biol. Med. 101 (2016), 116–128.
55. Amrani, A., Verdaguer, J., Thiessen, S., Bou, S., Santamaria, P., IL-1α IL-1β and IFN-γ mark β cells for Fas-dependent destruction by diabetogenic CD4+ T lymphocytes. J. Clin. Invest. 105:4 (2000), 459–468.
56. Rabinovitch, A., Suarez-Pinzon, W.L., Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem. Pharmacol. 55:8 (1998), 1139–1149.
57. Rabinovitch, A., An update on cytokines in the pathogenesis of insulin‐dependent diabetes mellitus. Diabetes Metab. Res. Rev. 14:2 (1998), 129–151.
58. Holstad, M., Sandler, S., A transcriptional inhibitor of TNF-α prevents diabetes induced by multiple low-dose streptozotocin injections in mice. J. Autoimmun. 16:4 (2001), 441–447.
59. Cailleau, C., Diu-Hercend, A., Ruuth, E., Westwood, R., Carnaud, C., Treatment with neutralizing antibodies specific for IL-1β prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 46:6 (1997), 937–940.
60. Khurana, A., Godugu, C., Alginate-Based Three-Dimensional In Vitro Tumor Models: A Better Alternative to Current Two-Dimensional Cell Culture Models, Alginates and Their Biomedical Applications. 2018, Springer, 157–183.
61. Baira, S.M., Khurana, A., Somagoni, J., Srinivas, R., Godugu, C., Talluri, M.K., First report on the pharmacokinetic profile of nimbolide, a novel anticancer agent in oral and intravenous administrated rats by LC/MS method. J. Chromatogr. B 1092 (2018), 191–198.
62. Bale, S., Khurana, A., Reddy, A.S.S., Singh, M., Godugu, C., Overview on therapeutic applications of microparticulate drug delivery systems. Crit. Rev. Ther. Drug Carr. Syst. 33:4 (2016), 309–361.
63. Saifi, M.A., Khurana, A., Godugu, C., Nanotoxicology: Toxicity and Risk Assessment of Nanomaterials, Nanomaterials in Chromatography. 2018, Elsevier, 437–465.